US5599712A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
Assignee: University of Pittsburgh
•
Filing: 1993-10-15
•
Granted: 1997-02-04
•
Expires: 2013-10-15
Abstract
Abstract A method of protecting a subject against an agent that elicits production of toxic free radicals, superoxide anions, or heavy metal cations in the subject consisting of the in vivo administration to the subject of a polynucleotide encoding a protein that is transiently expressed in said subject. The transiently expressed protein is capable of neutralizing or eliminating the toxic free radicals, superoxide anions or heavy metal cations that are elicited by the agent. This method is particularly useful in protecting cancer patients against the damaging effects of ionizing radiation and chemotherapeutic drugs.
Inventors
- 👤 Joel S. Greenberger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:10
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/44; A61K38/446; A61K38/17; A61K38/1703; A61K38/1709; A61K38/45; A61K48/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
168 words
A method for protecting a cancer subject against an agent that elicits production of a toxic species when said subject is exposed to said agent, wherein (i) said agent is selected from the group consisting of ionizing radiation, clinical radiation therapy, and a chemotherapeutic drug and, (ii) said toxic species is selected from the group consisting of a free radical, a superoxide anion, and a heavy metal cation, said method comprising the step of administering to said subject in vivo a pharmaceutical composition comprising (A) a polynucleotide that encodes a protein such that, in said subject, said protein is transiently expressed in said subject, wherein said protein (i) interacts with said toxic species to provide a protection therefrom and (ii) is selected from a group consisting of gamma glutamyl transpeptidase, manganese superoxide dismutase, and metallothionein; (B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and a replication-deficient adenovirus vector; and (C) said administering is directed to the site of the tumor.
Claim 2
Independent Claim
168 words
A method for protecting a cancer subject against an agent that elicits production of a toxic species when said subject is exposed to said agent, wherein (i) said agent is selected from the group consisting of ionizing radiation, clinical radiation therapy, and a chemotherapeutic drug and, (ii) said toxic species is selected from the group consisting of a free radical, a superoxide anion, and a heavy metal cation, said method comprising the step of administering to said subject in vivo a pharmaceutical composition comprising (A) a polynucleotide that encodes a protein such that, in said subject, said protein is transiently expressed in said subject, wherein said protein (i) interacts with said toxic species to provide a protection therefrom and (ii) is selected from a group consisting of gamma glutamyl transpeptidase, manganese superoxide dismutase, and metallothionein; (B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and a replication-deficient adenovirus vector; and (C) said administering is directed to the site of the tumor.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein said agent is ionizing radiation.
Claim 4
Dependent Claim
13 words
The method of claim 2, wherein said ionizing radiation is clinical radiation therapy.
Claim 5
Dependent Claim
12 words
The method of claim 1, wherein said agent is a chemotherapeutic drug.
Claim 6
Dependent Claim
12 words
The method of claim 1, wherein said administering is achieved through inhalation.
Claim 7
Dependent Claim
10 words
The method of claim 1, wherein said administering is intrarectal.
Claim 8
Dependent Claim
10 words
The method of claim 1, wherein said administering is intravesicle.
Claim 9
Dependent Claim
17 words
The method of claim 1, wherein said polynucleotide is a cDNA and said vehicle is a liposome.
Claim 10
Dependent Claim
19 words
The method of claim 1, wherein said polynucleotide is a cDNA and said vehicle is a replication-deficient adenovirus vector.
Claim 11
Dependent Claim
12 words
The method of claim 1, wherein said protein is gamma glutamyl transpeptidase.
Claim 12
Dependent Claim
12 words
The method of claim 1, wherein said protein is manganese superoxide dismutase.
Claim 13
Dependent Claim
10 words
The method of claim 1, wherein said protein is metallothionein.
Claim 14
Dependent Claim
37 words
The method of claim 1, wherein said pharmaceutical composition comprises a mixture of polynucleotides selected from the group consisting of a polynucleotide encoding gamma glutamyl transpeptidase, a polynucleotide encoding manganese superoxide dismutase and a polynucleotide encoding metallothionein.
Claim 15
Dependent Claim
16 words
The method of claim 1, wherein said pharmaceutical composition comprises a polynucleotide encoding gamma glutamyl transpeptidase.
Claim 16
Dependent Claim
16 words
The method of claim 1, wherein said pharmaceutical composition comprises a polynucleotide encoding manganese superoxide dismutase.
Claim 17
Dependent Claim
14 words
The method of claim 1, wherein said pharmaceutical composition comprises a polynucleotide encoding metallothionein.
Claim 18
Dependent Claim
12 words
The method of claim 1, wherein said subject is a cancer patient.
Claim 19
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is a lung cancer patient.
Claim 20
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is a prostate cancer patient.
Claim 21
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is a cervical cancer patient.
Claim 22
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is an endometrial cancer patient.
Claim 23
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is an ovarian cancer patient.
Claim 24
Dependent Claim
14 words
The method of claim 17, wherein said cancer patient is a bladder cancer patient.
Claim 25
Dependent Claim
18 words
The method of claim 1, wherein said administering is performed prior to said subject's exposure to said agent.
Claim 26
Dependent Claim
122 words
A pharmaceutical composition comprising: (A) a polynucleotide that encodes a protein such that said protein is transiently expressed in a cancer subject exposed to an agent that elicits production of a toxic species selected from the group consisting of a free radical, a superoxide anion, and a heavy metal cation, wherein (i) said agent is selected from the group consisting of ionizing radiation, clinical radiation therapy, and a chemotherapeutic drug and, (ii) said protein (a) interacts with said toxic species to provide protection therefrom and (b) is selected from a group consisting gamma glutamyl transpeptidase, manganese superoxide dismutase, and metallothionein; and (B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and a replication-deficient adenovirus vector.
Claim 27
Dependent Claim
122 words
A pharmaceutical composition comprising: (A) a polynucleotide that encodes a protein such that said protein is transiently expressed in a cancer subject exposed to an agent that elicits production of a toxic species selected from the group consisting of a free radical, a superoxide anion, and a heavy metal cation, wherein (i) said agent is selected from the group consisting of ionizing radiation, clinical radiation therapy, and a chemotherapeutic drug and, (ii) said protein (a) interacts with said toxic species to provide protection therefrom and (b) is selected from a group consisting gamma glutamyl transpeptidase, manganese superoxide dismutase, and metallothionein; and (B) a pharmaceutically acceptable vehicle for said polynucleotide wherein said vehicle is selected from a liposome and a replication-deficient adenovirus vector.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-04 | 2000-08-05 | 2001-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-04 | 2004-08-05 | 2005-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-04 | 2008-08-05 | 2009-02-04 | $7700.00 | Window Closed / Lapsed |